Pharmaceutical stalwart Sanofi (NYSE:SNY) recently lost patent exclusivity on some enormously successful drugs -- including multibillion-dollar blood thinners Plavix and Lovenox. However, shares of this company have soared more than 30% in the past 12 months, and what many perceive as a stagnant big pharma has actually transformed itself in the last few years.

In this video, health-care analysts Max Macaluso and David Williamson discuss Sanofi's innovative approach to R&D and how its Genzyme acquisition has potentially set the company up for more growth in the years to come.

David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.